Semler Scientific, Inc. (NASDAQ: SMLR) provides diagnostic and testing services to healthcare insurers and physician groups. Its mission is to develop, manufacture and market innovative proprietary products and services that assist healthcare providers in evaluating and treating chronic diseases. The company’s first patented and U.S. FDA cleared product measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease. In March 2015, the FDA granted 510(k) clearance for the next generation version of this product named QuantaFlo™, which was commercially launched in August 2015. In April 2015, the company launched its multi-test service offering, WellChec™, to more comprehensively evaluate patients for chronic disease. For more information, visit the company’s website at www.semlerscientific.com